Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: Where are we now?

Supportive Care in Cancer

Volumn 18, Issue 5, 2010, Pages 529-541

  Aapro, Matti ^a   Crawford, Jeffrey ^b   Kamioner, Didier ^c  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c SOS Main Hôpital privé Ouest Parisien   (France)

Author keywords

Cancer treatment; Colony stimulating factors; Guidelines; Neutropenia

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE;

ANEMIA; ANOREXIA; ASTHENIA; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA; CLINICAL EVALUATION; CLINICAL PRACTICE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; LEUKOCYTOSIS; LEUKOPENIA; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; GUIDELINES AS TOPIC; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; NEOPLASMS; NEUTROPENIA; RISK ASSESSMENT; UNITED STATES;

EID: 77953613020     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-0816-y     Document Type: Review

References (108)

1. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) in cidence, cost, and mortality of neutropenia hospitalizationasso ciated with chemotherapy. Cancer 103:1916-1924
2. Courtney DM, Aldeen AZ, Gorman SM, Handler JA, TrifilioSM, Parada JP, Yarnold PR, Bennett CL (2007) Cancer associated neutropenic fever: Clin ical outcome and economiccosts of emergency department care. Oncologist 12:1019-1026
3. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrileneutropenia in adult cancer patients. Cancer 106:2258-2266
4. Mayordomo JI, Castellanos J, Pernas S, Ruiz-Borrego M,Velasco A, Frau A, Lamas MJ, Lara N, Gasquet JA, Sánchez J (2006) Cost analysis of febrile neutropenia management of breast cancer patients in clin ical practice in Spa in. Annoncol 17 (Suppl 9):ix190-ix195, Abstract 617P
5. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, CooksleyC, Avritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ,Talcott JA, Rolstonk (2008) Outcomes and cost of outpatient or in patient management of 712 patients with febrile neutropenia. J Clinoncol 26:606-611
6. Link BK, Budd GT, Scott S, Dickman E, Paul D, Lawless G, LeeMW, Fridman M, Ford J, Carter WB (2001) Deliver ing adjuvantchemotherapy to women with early-stage breast carc inoma:current patterns of care. Cancer 92:1354-1367
7. Bosly A, Bron D, Van Ho A, De Bock R, Berneman Z, FerrantA, Kaufman L, Dauwe M, Verhoefg (2007) Achievement of optimal average relative dose in tensity and correlation with survivalin diffuse large B-cell lymphoma patients treated with CHOP. Ann Hemato l 87:277-283
8. Pettengell R, SchwenkglenKs M, Leonard R, Bosly A, ParidaensR, Constenla M, Szucs TD, Jackisch C (2008) Neutropeniaoccurrence and predicto rs of reduced chemotherapy delivery:results from the in C-EU prospective observational European neutropenia study Support Care Cancer 16 1299-1309.
9. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, BrambillaC (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracilin node-positive breast cancer: Theresults of 20 years of follow-up. N Engl J Med 332:901-906
10. Lee KW, Kim DY, Yun T, Kim DW, Kim TY, Yoon SS, Heo DS,Bang YJ, Park S, Kim BK, Kim nk (2003) Doxorubic in -basedchemotherapy for diffuse large B-cell lymphoma in elderlypatients: Comparisonof treatment outcomes between youngand elderly patients and the significance of doxorubic in dosage.Cancer 98:2651-2656
11. Kwa K LW, Halpern J, Olshen RA, Horning SJ (1990) Prognosticsignificance of actual dose in tensity in diffuse large-cell lymphoma:results of a tree-structured survival analysis. J Clinoncol 8:963-977
12. Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A,Rosello S, García-Garre E, Martín P, Bosch A, Lluch A (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant sett ing improves outcome of breast cancer patients.Breast Cancer Res Treat 114:479-484
13. Pettengell R, SchwenkglenKs M, Bosly A (2008) Associationof reduced relative dose in tensity and survivalin lymphomapatients receiv ing CHOP-21 chemotherapy. Ann Hemato l 87:429-430
14. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I,Kris M, Grous J, Picozzi V, Rauschg et al (1991) Reduction by granulocyte colony-stimulat ing facto r of fever and neutropenia in duced by chemotherapy in patients with small-cell lung cancer.N Engl J Med 325:164-170
15. Crawford J (2002) Neutrophil growth facto rs. Curr Hemato l Rep1:95-102
16. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J,Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J,Weber DC, Zielinski C (2006) EORTC guidelines for the use of granulocyte-colony stimulat ing facto r to reduce the in cidence of chemotherapy- in duced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453
17. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO,Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ,Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L,Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ,Woznia K AJ, Wolff AC (2006) 2006 Update of recommendationsfor the use of white blood cell growth facto rs: An evidence-basedclin ical practice guideline. J Clinoncol 24:3187-3205
18. National Comprehensive Cancer Network (2010) Practice Guidelines inoncology v.1.2010. Myeloid Growth Facto rs. Availableat: Http://www.nccn.org/ professionals/physician-gls/PDF/myeloid-growth.pdf. Accessed 2 Feb 2010
19. Greil R, Psena K O, Roila F (2008) Hemato poietic growth facto rs:ESMO recommendations for the applications. Annoncol 19 (Suppl 2):ii116-ii118
20. Carrato A, Paz-Ares Rodriguez L, Rodriguez Lescure A,Fernandez C, de Tejerina AM, Diaz Rubio Garcaa E, PerezSegura P, Constenla Figueiras M, García Carbonero R, GómezCod in a J, Lluch Hernández A, Maroto Rey JP, Martín JiḿnezM, Mayordomo Cámara JI, Morenonogueira JA, RuedaDomínguez A (2009) Spanish Society of Medical Oncologyconsensus for the use of haemato poietic colony-stimulat in gfacto rs in cancer patients. Clin Transl Oncol 11:446-454
21. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD,Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL3rd, Winn RJ, Woznia K AJ, Somerfield MR (2000) Update of recommendations for the use of hemato poietic colonystimulat in gfacto rs: Evidence-based, clin ical practice guidelines.American society of clin ical oncology growth facto rs expertpanel. J Clinoncol 18:3558-3585
22. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrileneutropenia in patients with breast cancer: A multicenter, doubleblin d,placebo-controlled phase III study. J Clinoncol 23:1178-1184
23. Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, WilschutFA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J,Adang EM, Bootsma GP, Tjan-Heijnen VC (2005) Preventionof chemotherapy- in duced febrile neutropenia by prophylactic antibioticsplus or m in us granulocyte colony-stimulat ing facto r in small-cell lung cancer: A Dutch randomized phase III study. J Clinoncol 23:7974-7984
24. Ajani JA (2008) Optimiz ing docetaxel chemotherapy in patientswith cancer of the gastric and gastroesophageal junction:evolutionof the docetaxel, cisplat in , and 5-fluorouracil regimen.Cancer 113:945-955
25. Posner M, Vermorken JB (2008) in duction therapy in the modern era of comb in ed-modality therapy for locally advancedhead and neck cancer. Sem inoncol 35:221-228
26. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R,Degard in M, Stewart JS, Jelic S, Betka J, Preiss JH, van denWeyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A,Desaunois I, Bernier J, Lefebvre JL (2007) Cisplat in , fluorouracil, and docetaxelin unresectable head and neck cancer. N Engl J Med 357:1695-1704
27. Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, BoccadoroM, Palumbo A (2008) Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer ther8:865-874
28. Palumbo A, Dimopoulos M, Miguel JS, Harousseau JL, Attal M,Husse in M, Knop S, Ludwig H, von Lilienfeld-to al M,Sonneveld P (2009) Lenalidomide in comb in ation with dexamethasonefor the treatment of relapsed or refracto ry multiplemyeloma. Blood Rev 23:87-93
29. Pal R, Roodman GD, Mapara M, Mocs in ski L, List AF, LentzschS (2008) Immunomodulato ry derivatives of thalidomide (IMiD) - in duced neutropenia is associated with PU1 downregulation andmyeloid maturation arrest. Blood 112:Abstract 845
30. Repetto L, Biganzoli L, Koehne CH, Luebbe AS, Soubeyran P,Tjan-Heijnen VC, Aapro MS (2003) EORTC Cancer in the ElderlyTask Force guidelines for the use of colony-stimulat ing facto rs in elderly patients with cancer. Eur J Cancer 39:2264-2272
31. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP,Weaver C, to mia K E, Al-Tweigeri T, Chap L, Juhos E, Guev in R, Howell A, Fornander T, Ha in sworth J, Coleman R, V in holesJ, Modiano M, P in ter T, Tang SC, Colwell B, Prady C,Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, LoretC, Rup in M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C (2005) Adjuvant docetaxel for node-positive breast cancer. NEngl J Med 352:2302-2313 (Pubitemid 40740554)
32. Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E,Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C,Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J,Arcusa A, López-Vega JM, Muñoz M, Mel JR (2006) to xicityand health-related quality of life in breast cancer patientsreceiv ing adjuvant docetaxel, doxorubic in , cyclophosphamide (TAC) or 5-fluorouracil, doxorubic in and cyclophosphamide (FAC): Impact of adDing primary prophylactic granulocytecolonystimulat ing facto r to the TAC regimen. Annoncol17:1205-1212
33. von Minckwitz G, K̈mmel S, du Bois A, Eiermann W,Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, JackischC, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM,Kaufmann M (2008) Pegfilgrastim +/- cipr of loxac in for primaryprophylaxis with TAC (docetaxel/doxorubic in /cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Annoncol 19:292-298
34. Romieu G, Clemens M, Mahlberg R, Fargeot P, Constenla M,Schutte M, Easton V, Skacel T, Bacon P, Brugger W (2007) Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase2 trial. Crit Rev Oncol Hemato l 64:64-72
35. Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, DreilingL, Erchler WB (2007) Elderly cancer patients receiv in gchemotherapy benefit from first-cycle pegfilgrastim. Oncologist12:1416-1424
36. Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D,Kaufmann M, Eggemann H, Nekljudova V, Sommer H, KiechleM, K̈mmel S (2008) Clin ical feasibility of (neo) adjuvanttaxane-based chemotherapy inolder patients: Analysis of >4,500 patients from four German randomized breast cancertrials. Breast Cancer Res 10:R77
37. Aapro M, SchwenkglenKs M, Lyman GH, Lopez Pousa A,Lawrinson S, Skacel T, et al (2010). Pegfilgrastim primaryprophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiv ing chemotherapy. Crit RevOncol Hemato l ( in press)
38. Crawford J, Dale DC, Kuderer NM, Cula Kova E, PoniewierskiMS, Wolff D, Lyman GH (2008) Risk and tim ing of neutropenicevents in adult cancer patients receiv ing chemotherapy: Theresults of a prospective nationwide study of oncology practice. JNatl Compr Canc Netw 6:109-118
39. Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmonk,Sandor D, Reardong (2008) Identify ing patients at high risk forneutropenic complications dur ing chemotherapy for metastaticbreast cancer with doxorubic inor pegylated liposomal doxorubic in :the development of a prediction model. Am J Clinoncol31:369-374
40. Jenkins P, Freeman S (2008) Pretreatment haemato logicallaborato ry values predict for excessive myelosuppression in patients receiv ing adjuvant FEC chemotherapy for breast cancer.Annoncol 20:34-40
41. Cula Kova E, Wolff D, Poniewierski M, Crawford J, Dale D,Lymang (2008) Facto rs related toneutropenic events in earlystage breast cancer patients. J Clinoncol 26 (Suppl 15):Abstract634
42. Shayne M, Crawford J, Dale DC, Cula Kova E, Lyman GH (2006) Predicto rs of reduced dose in tensity in patients with e arly-stage breast cancer receiv ing adjuvant chemotherapy.Breast Cancer Res Treat 100:255-262
43. Ziepert M, Schmits R, Trumper L, Pfreundschuh M, Loeffler M (2008) Prognostic facto rs for hemato to xicity of chemotherapy in aggressive non-Hodgk in 's lymphoma. Annoncol 19:752-762
44. Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R,Paridaens R, Constenla M, SchwenkglenKs M (2009) Multivariateanalysis of febrile neutropenia occurrence in patients with non-Hodgk in lymphoma: Data from the in C-EU Prospective ObservationalEuropean Neutropenia Study. Br J Haemato l 144:677-685
45. Lyman GH, Lyman CH, Agboola O (2005) Risk models forpredict ing chemotherapy- in duced neutropenia. Oncologist10:427-437
46. Lyman GH, Crawford J, Kuderer NM, Wolff D, Cula Kova E,Poniewierski MS, Dale DC (2008) F in al risk prediction modelfor neutropenic complications in patients receiv ing cancerchemotherapy. Blood 112:Abstract 1312
47. Shayne M, Cula Kova E, Dale DC, Poniewierski MS, Wolff DA,Crawford J, Lyman H (2007) A validated risk model for earlyneutropenic events inolder cancer patients receiv ing systemicchemotherapy. J Clinoncol 25 (Suppl 18):Abstract 9036
48. Norton L (1988) A Gompertzian model of human breast cancergrowth. Cancer Res 48:7067-7071
49. Goldie JH, Coldman AJ (1979) A mathe matic model for relat in gthe drug sensitivity of tumors to the ir spontaneous mutation rate.Cancer Treat Rep 63:1727-1733
50. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP,Gradishar WJ, Davidson NE, Martino S, Livingston R,Ingle JN,Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sarto r CI,Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduledand sequential versus concurrent comb in ation chemotherapy asposto perative adjuvant treatment of node-positive primary breastcancer: First report of in tergroup Trial C9741/Cancer andLeukemia Group B Trial 9741. J Clinoncol 21:1431-1439
51. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC,Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H,Hasenclever D, Schmitz N, Loeffler M (2004) Two-weekly or 3-weekly CHOP chemotherapy with or with out eto poside for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641 (Pubitemid 38970554)
52. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC,Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D,538 Support Care Cancer (2010) 18:529-541Schmitz N, Glass B, R̈be C, Loeffler M (2004) Two-weekly or3-weekly CHOP chemotherapy with or with out eto poside for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633
53. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W,Stephens RJ (2000) Improv ing survival with out reduc ing quality of life in small-cell lung cancer patients by in creas ing the dose in tensity of chemotherapy with granulocyte colony-stimulat in gfacto r support: Results of a British Medical Research CouncilMulticenter Randomized Trial. Medical Research Council LungCancer Work ing Party. J Clinoncol 18:395-404
54. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M,Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N,Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, MertelsmannR, Tr̈mper L, Balleisen L, Liersch R, Metzner B,Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, FellerAC, Loeffler M (2008) Six versus eight cycles of bi-weeklyCHOP-14 with or with out rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlledtrial (RICOVER-60). Lancet Oncol 9:105-116
55. Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA,Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK,Sonneveld P, van Imhoff GW (2007) in tensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with in termediate-risk aggressive non-Hodgk in lymphoma: A phase 3 trial of the Dutch-BelgianHemato -Oncology Cooperative Group (HOVON). Blood109:2759-2766
56. Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L,Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E,Lazzarino M (2006) Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: Aphase II study of feasibility and to xicity. Haemato logica 91:496-502
57. Mey UJ, Maier A, Schmidt-Wolf IG, Ziske C, Forstbauer H,Banat GA, Reber M, Strehl JW, Gorschlueter M (2007) Pegfilgrastim as hemato poietic support for dose-dense chemoimmunotherapywith R-CHOP-14 as first-line therapy in elderlypatients with diffuse large B cell lymphoma. Support Care Cancer 15:877-884
58. Wolf M, Bentley M, Marlton P, Horvath N, Lewis ID, SpencerA, Herrmann R, Arthur C, Durrant S, vankerkhoven M,MacMillan J, Mrongovius R (2006) Pegfilgrastim to supportCHOP-14 in elderly patients with non-Hodgk in 's lymphoma.Leuk Lymphoma 47:2344-2350
59. Hartmann F, Zeynalova S, Nickenig C, Reiser M, Lengfelder E,Duerk H, de Witt M, Schubert J, Loeffler M, Pfreunschuh MG (2007) Peg-filgrastim (Peg-F) on day 4 of (R-) CHOP-14chemotherapy compared to day 2 in elderly patients with diffuselarge B-cell lymphoma (DLBCL): Results of a randomized trial of the German high-grade non-Hodgk in 's lymphoma study group (DSHNHL). J Clinoncol 25 (Suppl 18):Abstract 19511
60. Engert A, Bredenfeld H, Dohner H, Ho AD, Schmitz N, BergerD, Bacon P, Skacel T, Easton V, Diehl V (2006) Pegfilgrastimsupport for full delivery of BEACOPP-14 chemotherapy forpatients with high-risk Hodgk in 's lymphoma: Results of a phaseII study. Haemato logica 91:546-549
61. Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E,Teissier E, Berdah JF, Fabbro M, Valenza B, Herait P, Jehl V,Buyse M (2007) Dose-dense adjuvant chemotherapy in nodepositivebreast cancer: Docetaxel followed by epirubic in /cyclophosphamide (T/EC) , or thereverse sequence (EC/T) , every2 weeks, versus docetaxel, epirubic in and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.Annoncol 18:52-57
62. Wildiers H, Dirix L, Neven P, Prove A, Clement P, Squifflet P,Amant F, Skacel T, Paridaens R (2009) Delivery of adjuvantsequential dose-dense FEC-Doc to patients with breast cancer isfeasible, but dose reductions and to xicity are dependent ontreatment sequence. Breast Cancer Res Treat 114:103-112
63. Kahan Z, Spanik S, Wagnerova M, Skacel T, Planko B, FitzthumE, Lindner E, Soldatenkova V, Zielinski CC, Brodowicz T (2008) Feasibility of two dose-dense FEC regimens with growthfacto r support for adjuvant therapy in patients with early breastcancer: Results from a randomised study of the Central EuropeanCooperative Oncology Group (CECOG). Breast Cancer ResTreat 112:557-563
64. Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH,Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE,Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP (2005) Efficacy of pegfilgrastim and darbepoet in alfa ashemato poietic support for dose-dense every-2-week adjuvantbreast cancer chemotherapy. J Clinoncol 23:8340-8347
65. Pirker R, Ulsperger E, Messner J, Aigner K, Forstner B, BaconP, Easton V, Skacel T (2006) Achiev ing full-dose, on-scheduleadm in istrationof ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung184:279-285
66. Trumper L, Zwick C, Ziepert M, Hohloch K, Schmits R, MohrenM, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M,Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M (2008) Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgk in 's lymphoma: I. A randomized doseescalation and feasibility study with bi- and tri-weekly regimens.Annoncol 19:538-544 (Pubitemid 351325677)
67. Pfreundschuh M, Zwick C, Zeynalova S, Duhrsen U, PflugerKH, Vrieling T, Mesters R, Mergenthaler HG, Einsele H, BentzM, Lengfelder E, Tr̈mper L, R̈be C, Schmitz N, Loeffler M (2008) Dose-escalated CHOEP for the treatment of youngpatients with aggressive non-Hodgk in 's lymphoma: II. Results of therandomized high-CHOEP trial of the German High-GradeNon-Hodgk in 's Lymphoma Study Group (DSHNHL). Annoncol 19:545-552
68. Earl HM, Hiller L, Dunn JA, Bathers S, Harvey P, Stanley A,Grieve RJ, Agrawal RK, Fernando in , Brunt AM, McAdam K,O'Reilly S, Rea DW, Spooner D, Poole CJ (2008) NEAT:National Epirubic in Adjuvant Trial-to xicity, delivered dose in tensity and quality of life. Br J Cancer 99:1226-1231
69. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulat ing facto r onfebrile neutropenia and mortality in adult cancer patients receiv in gchemotherapy: A systematic review. J Clinoncol 25:3158-3167
70. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J (2007) Meta-analysis: Effect of prophylactic hemato poieticcolony-stimulat ing facto rs on mortality and outcomes of infection.Ann in tern Med 147:400-411
71. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A (2008) Granulopoiesis-stimulat ing facto rs to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database SystRev (4):CD003189. http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003189/frame.html
72. Dubois RW, Pinto LA, Bernal M, Badamgarav E, Lyman GH (2004) Benefits of GM-CSF versus placebo or G-CSF in reduc ing chemotherapy- in duced complications: A systematicreview of the literature. Supportive Cancer ther 2 (1):34-41
73. Lyman G, Kuderer N, Crawford J, Wolff D, Cula Kova E,Poniewierski M, Dale DC (2008) Impact of pegfilgrastim onearly all-cause mortality in patients receiv ing cancer chemotherapy.J Clinoncol 26 (Suppl 15):Abstract 6552
74. Yang BB, Kido A, Shibata A (2007) Serum pegfilgrastimconcentrations dur ing recovery of absolute neutrophil count in Support Care Cancer (2010) 18:529-541 539patients with cancer receiv ing pegfilgrastim after chemotherapy.Pharmacotherapy 27:1387-1393
75. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lymang (2007) Comparisonof pegfilgrastim with filgrastim on febrile neutropenia,grade IV neutropenia and bone pa in : A meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283-2295
76. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, GatzemeierU, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D et al (1993) Recomb in ant granulocyte colony stimulat ing facto rreduces the infectious complications of cyto to xic chemotherapy.Eur J Cancer 29A:319-324
77. Morrison VA, Wong M, Hershman D, Campos LT, Ding B,Malin J (2007) Observational study of the prevalence of febrileneutropenia in patients who received filgrastim or pegfilgrastimassociated with 3-4 week chemotherapy regimens in communityoncology practices. J Manag Care Pharm 13:337-348
78. Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with Increased risk of hospitalization? Ann Pharmacother 40:402-407
79. Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M,Stolshek BS (2003) Days of prophylactic filgrastim use to reducefebrile neutropenia in patients with non-Hodgk in 's lymphomatreated with chemotherapy. J Manag Care Pharm 9 (2 Suppl ):15-21
80. von Minckwitz G, SchwenkglenKs M, Skacel T, Lyman GH,Pousa AL, Bacon P, Easton V, Aapro MS (2009) Febrileneutropenia and related complications in breast cancer patientsreceiv ing pegfilgrastim primary prophylaxis versus currentpractice neutropaenia management: Results from an in tegratedanalysis. Eur J Cancer 45:608-617
81. Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A,Osterg (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumorsreceiv ing pegfilgrastim or filgrastim prophylaxis: A retrospectivecohort study. Clin ther 31:1069-1081
82. Del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008) XM02 is superior to placebo and equivalent toneupogen in reduc ing the durationof severe neutropenia and the in cidence of febrile neutropenia in cycle 1 in breast cancer patientsreceiv ing docetaxel/doxorubic in chemotherapy. BMC cancer8:332
83. Mellstedt H, Niederwieser D, Ludwig H (2008) the challenge of biosimilars. Annoncol 19:411-419
84. Amgen (2008) Neulasta Summary of Product Characteristics.Available at: Http://www.ema.europa.eu/humandocs/PDFs/EPAR/neulasta/emea-combined-h420en.pdf. Accessed 2 Feb 2010
85. Amgen (2009) Neupogen summary of product characteristics.http://emc. medicines.org.uk/medicine/7907/SPC/ Neupogen+30MU+and+48MU+Vials+and+SIngleject+Syringes/. Accessed2 Feb 2010
86. Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T,Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M,Budman DR, Hackett J, Brassard M, Yang BB, Liang BC (2002) Comparable efficacy and safety pr of iles of once-per-cyclepegfilgrastim and daily in jection filgrastim in chemotherapy in ducedneutropenia: A multicenter dose-f in Ding study in womenwith breast cancer. Annoncol 13:903-909
87. Markman M (2003) Manag ing taxane to xicities. Support Care Cancer 11:144-14788.
88. Paba C, Sachdev J, Kronish L, Jahanzeb M, Waheed S (2008) Empiric dose reductionof pegfilgrastim in breast cancer patientsreceiv ing cyto to xic chemotherapy. J Clinoncol 26 (Suppl 15):Abstract 20636
89. Ip EJ, Lee-Ma A, Troxell LS, Chan J (2008) Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubic in , and cyclophosphamide. Am J Health Syst Pharm 65:1552-1555
90. Chugai Pharma (2009) Granocyte (lenograstim) Summary of product characteristics. http://emc.medic in es.org.uk/emc/assets/c/html/DisplayDoc.asp? DocumentID=8347. Accessed 2 Feb2010
91. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J,Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, NeumannTA, Hill LR, Liang BC (2002) Blin ded, randomized, multicenterstudy to evaluate sIngle adm in istration pegfilgrastim once percycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clinoncol 20:727-731
92. Yang BB, Hill R, Hollifield A, Green M, Holmes F, Sheridan W,Barnes RD (2003) Pegfilgrastim serum concentrations on the twelfth day after dos ing are unlikely to stimulate granulopoiesis:a retrospective analysis of 6 clin ical trials in a variety of cancerpopulations. Blood 102:Abstract 1918
93. Tyshler LB, Longton GM, Ellis GK, Livingston RB (1996) Falsepositive tumor markers: Elevation in patients with breast canceron FAC-type chemotherapy and correlation with the development of hand-foot syndrome. in t J Biol Markers 11:203-206
94. Briasoulis E, Andreopoulou E, Tolis CF, Baira Ktari E, KatsarakiA, Dimopoulos MA, Fountzilas G, Seferiadis C, Pavlidis N (2001) G-CSF in duces elevationof circulat ing CA 15-3 in breastcarc inoma patients treated in an adjuvant sett in g. Cancer 91:909-917
95. Pentherouda Kis G, Malamou-Mitsi V, Briasoulis E, Damala K,Vassou A, Vartholomatos G, Kolaitis N, Pavlidis N (2004) the neutrophil, not the tumor: Serum CA 15-3 elevation as a result of granulocyte-colony-stimulat ing facto r- in duced neutrophil MU1Coverexpression and neutrophilia in patients with breast carc inomareceiv ing adjuvant chemotherapy. Cancer 101:1767-1775
96. Saura C, Vilar E, Cortes J, Bellet M, Ocana A, Gomez P, BaselgaJ (2006) Pegfilgrastim in duces elevationof serum CA 15-3 in breast carc inoma patients after receiv ing dose-dense adjuvantchemotherapy. J Clinoncol 24 (Suppl 18):Abstract 8595
97. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY,McBride R, Bennett CL, Grann VR (2007) Acute myeloidleukemia or myelodysplastic syndrome follow ing use of granulocytecolony-stimulat ing facto rs dur ing breast cancer adjuvantchemotherapy. J Natl Cancer in st 99:196-205
98. Valagussa P, Moliterni A, Terenziani M, Zambetti M, BonadonnaG (1994) Second malignancies follow ing CMF-basedadjuvant chemotherapy in resectable breast cancer. Annoncol5:803-808
99. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC,Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M,Nilsson J, Onida F, Piccart M, Shepherd L, therasse P, Wils J,Rogers D (2005) Risk of acute myeloid leukemia and myelodysplasticsyndrome in trials of adjuvant epirubic in for early breastcancer: Correlation with doses of epirubic in and cyclophosphamide.J Clinoncol 23:4179-4191
100. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH (2007) Acute myeloid leukemia after adjuvant breast cancer therapy inolder women: UnderstanDing risk. J Clinoncol 25:3871-3876
101. Clamp AR, Ryder WD, Bhattacharya S, Pettengell R, RadfordJA (2008) Patterns of mortality after prolonged follow-up of arandomised controlled trial us ing granulocyte colony-stimulat in gfacto r to ma in ta in chemotherapy dose in tensity in non-Hodgk in 'slymphoma. Br J Cancer 99:253-258
102. Lyman GH, Dale DC, Wolff D, Cula Kova E, Kuderer NM,Poniewierski MS, Crawford J (2008) Standard versus dose in tensifiedchemotherapy with granulocyte colony-stimulat in gfacto r for malignant lymphoma: Evaluationof risk for acutemyeloid leukemia or myelodysplastic syndrome. Blood 112:Abstract 2390
103. Touw IP, Bontenbal M (2007) Granulocyte colony-stimulat in gfacto r: Key (f) acto r or in nocent by stander in the development of secondary myeloid malignancy? J Natl Cancer in st 99:183-186
104. Viñolas N, Gúrpide A, Frau A, González Larriba J, Lamas M,Alvarez F, et al (2007) Clin ical and economic impact of febrileneutropenia management of lung cancer patients in clin icalpractice in Spa in (Abstract 6567). 14th European CancerConference; 23-27 September, Barcelona, Spa in
105. Durand-Zaleski I, Vainchtock A, Bogillot O (2007) L'utilisationde la base nationale PMSI pour d́term in er le côut d'unsymptôme: Le cas de la neutroṕnie f́brile. J Econ Med25:269-280
106. Eldar-Lissai A, Cosler LE, Cula Kova E, Lyman GH (2008) Economic analysis of prophylactic pegfilgrastim in adult cancerpatients receiv ing chemotherapy. Value Health 11:172-179
107. Lyman G, Lalla A, Barron R, Dubois RW (2009) Costeffectiveness of pegfilgrastim versus 6-day filgrastim primaryprophylaxis in patients with non-Hodgk in 's lymphoma receiv in gCHOP-21 in United States. Curr Med Res Opin 25:401-411
108. Ramsey SD, Liu Z, Boer R, Sullivan SD, Malin J, Doan QV,Dubois RW, Lyman GH (2009) Cost-effectiveness of primaryversus secondary prophylaxis with pegfilgrastim in women with e arly-stage breast cancer receiv ing chemotherapy. Value Health 12: 217-225